Menu

Anheuser-Busch Won’t Fund Controversial NIH Alcohol Study

The company’s announcement comes weeks after enrollment was suspended.

Jun 11, 2018
Shawna Williams

ISTOCK, DEBRAMILLETUpdate (June 18): STAT News reports that NIH has shut down the alcohol study. Lawrence Tabak, the head of a task force charged with examining the study, says, “the nature of the engagement with industry representatives calls into question the impartiality of the process.”


Anheuser-Busch InBev has withdrawn a $15-million funding commitment for a mammoth National Institutes of Health study on the effects of moderate alcohol consumption, The New York Times reports. The company’s announcement, made on Friday (June 8), comes after the planned study drew scrutiny over potential conflicts of interest on the part of NIH, which had courted corporate sponsors with the prospect of producing evidence of health benefits of regular drinking.


See “NIH Turned Down Investigators Who Provoked Ire From Alcohol Industry


The planned $100-million study, administered by the NIH’s National Institute of Alcohol Abuse and Alcoholism (NIAAA) would assign thousands of participants either to have an alcoholic drink every day or abstain, and track their health outcomes and mortality over six years. The New York Times reported in March that in an effort to get beverage makers to pick up most of the tab, NIAAA scientists met with industry leaders and “gave talks strongly suggesting that the study’s results would endorse moderate drinking as healthy.” STAT News later found that a separate funding request from researchers whose work had drawn criticism from industry had been turned down by NIAAA.


Following the revelations, NIH Director Francis Collins announced that the agency was reviewing the process around funding for the trial and would determine whether it should proceed, and that enrollment had been suspended for the time being, The Washington Post reported last month.


Anheuser-Busch announced its decision to withdraw funding in a letter to the Foundation for the National Institutes of Health. According to the Times, the letter concludes, “Unfortunately, recent questions raised around the study could undermine its lasting credibility, which is why we have decided to end our funding.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.